In agreement with what we observed in local tumors (Supplementary Figure 1a, c), the combination therapy also failed to further increase the Tconv/Treg ratio in distant tumors compared to ZD55-IL-24 therapy alone or anti-PD-1 therapy alone (Supplementary Figure 2a, c), suggesting that ZD55-IL-24 was unable to help PD-1 blockade to further improve the tumor immune microenvironment in distant tumors as well. The gene discussed is IL24; the disease is neoplasm.